Application of microbial genomic science to advanced therapeutics

Annual Review of Medicine

Volumn 56, Issue , 2005, Pages 459-474

  Fraser, Claire M ^a   Rappuoli, Rino ^b  

^a J CRAIG VENTER INSTITUTE   (United States)

^b CHIRON VACCINES   (Italy)

Author keywords

Comparative genomics; Pathogens; Proteome; Transcriptome; Vaccines

Indexed keywords

ANTIBIOTIC AGENT; BCG VACCINE; CHOLERA VACCINE; DIPHTHERIA TETANUS VACCINE; EPITOPE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PROTEOME; RABIES VACCINE; TRANSCRIPTOME; VACCINE;

BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER MODEL; CORRELATION ANALYSIS; DIAGNOSTIC TEST; GENE SEQUENCE; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HAEMOPHILUS INFLUENZAE TYPE A; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; MICROBIAL GENETICS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL INFECTIONS; COMPUTER SIMULATION; DNA FINGERPRINTING; EPITOPES; GENOME, BACTERIAL; HUMANS; PROTEOME; SEQUENCE ANALYSIS; SPECIES SPECIFICITY; VACCINES, DNA; VACCINES, SYNTHETIC; VIRULENCE FACTORS;

EID: 14544284148     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.56.062904.144853     Document Type: Review

References (61)

1. Fleischmann RF, Adams MD, White O, et al. 1995. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269:496-512
2. Hood DW, Deadman ME, Jenning MP, et al. 1996. DNA repeats identify novel virulence genes in Haemophilus influenzae. Proc. Natl. Acad. Sci. USA 93:11121-25
3. Parkhill J, Wren BW, Mungall K, et al. 2000. The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature 403:665-68
4. Saunders NJ, Jeffries AC, Peden JF, et al. 2000. Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol. Microbiol. 37:207-15
5. Paulsen IT, Banerjei L, Myers GS, et al. 2003. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 299:2071-74
6. Hoffmaster AR, Ravel J, Rasko DR, et al. 2004. Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. Proc. Natl. Acad. Sci. USA 101:8449-54
7. Perna NT, Plunkett G 3rd, Burland V, et al. 2001. Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature 409:529-33
8. Deng W, Burland V, Plunkett G 3rd, et al. 2002. Genome sequence of Yersinia pestis KIM. J. Bacteriol. 184:4601-11
9. Parkhill J, Wren BJ, Thomson NR, et al. 2001. Genome sequence of Yersiniapestis, the causative agent of plague. Nature 413: 523-27
10. Nelson KE, Fouts DE, Mongodin EF, et al. 2004. Whole genome comparisons of serotype 4b and 1/2a strains of the food-borne pathogen Listeria monocytogenes reveal new insights into the core genome components of this species. Nucleic Acids Res. 32:2386-95
11. Grifantini R, Bartolini E, Muzzi A, et al. 2002. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat. Biotechnol. 20:914-21
12. Dietrich G, Kurz S, Hubner C, et al. 2003. Transcriptome analysis of Neisseria meningitidis during infection. J. Bacteriol. 185:155-64
13. Hughes D. 2003. Exploiting genomics, genetics, and chemistry to combat antibiotic resistance. Nat. Rev. Genet. 4:432-41
14. McDevitt D, Payne DJ, Holmes DJ, Rosenberg M. 2002. Novel targets for the future development of antibacterial agents. Symp. Ser. Soc. Appl. Microbiol. 31:28S-34S
15. Chan PF, Macarron R, Payne DJ, et al. 2002. Novel antibacterials: a genomics approach to drug discovery. Curr. Drug Targets Infect. Disord. 2:291-308
16. Karp PD, Riley M, Saier M, et al. 2002. The EcoCyc Database. Nucleic Acids Res. 30:56-58
17. Kanehisa M, Goto S, Kawashima S, et al. 2004. The KEGG resource for deciphering the genome. Nucleic Acids Res. Database issue:D277-80
18. Hutchison CA, Peterson SN, Gill SR, et al. 1999. Global transposon mutagenesis and a minimal Mycoplasma genome. Science 286:2165-69
19. Akerley BJ, Rubin EJ, Novick VL, et al. 2002. A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc. Natl. Acad. Sci. USA 99:966-71
20. Thanassi JA, Hartmann-Neumann SL, Dougherty TJ, et al. 2002. Identification of 113 conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae. Nucleic Acids Res. 30:3152-62
21. Ji Y, Zhang B, Van SF, et al. 2001. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293:2266-69
22. Merrell DS, Camilli A. 2000. Detection and analysis of gene expression during infection by in vivo expression technology. Philos. Trans. R. Soc. London 355:587-99
23. Hensel M, Shea JE, Gleeson C, et al. 1995. Simultaneous identification of bacterial virulence genes by negative selection. Science 269:400-3
24. Alksne L, Burgio P, Hu W, et al. 2000. Identification and analysis of bacterial secretion inhibitors utilizing a SecA-LacZ reporter fusion system. Antimicrob. Agents Chemother. 44:1418-27
25. Barrett JF, Goldschmidt RM, Lawrence LE, et al. 1998. Antimicrobial agents that inhibit two component signal transduction systems. Proc. Natl. Acad. Sci. USA 95: 5317-22
26. Payne DJ, Warren PV, Holmes DJ, et al. 2001. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov. Today 6:537-44
27. Paulsen IT. 2003. Multidrug efflux pumps and resistance: regulation and evolution. Curr. Opin. Microbiol. 6:446-51
28. Van Bambeke F, Glupczynski Y, Plesiat P, et al. 2003. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J. Antimicrob. Chemother. 51:1055-65
29. Deleted in proof
30. Paulsen IT, Sliwinski MK, Nelissen B, et al. 1998. Unified inventory of established and putative transporters encoded within the complete genome of Saccharomyces cerevisiae. FEMS Lett. 430:116-25
31. LeThomas I, et al. 2001. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxanin therapy. J. Antimicrob. Chemother. 48:553-55
32. Rappuoli R. 2000. Reverse vaccinology. Curr. Opin. Microbiol. 3:445-50
33. Balmer P, Borrow R, Miller E. 2002. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 51:717-22
34. Peltola H. 1998. Meningococcal vaccines. Current status and future possibilities. Drugs 55:347-66
35. Hayrinen J, Jennings H, Raff HV, et al. 1995. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J. Infect. Dis. 171:1481-90
36. Tettelin H, Saunders NJ, Heidelberg J, et al. 2000. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287:1809-15
37. Pizza M, Scarlato V, Masignani V, et al. 2000. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816-20
38. Goldschneider I, Gotschlich EC, Artenstein MS. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-26
39. Wizemann TM, Heinrichs JH, Adamou JE, et al. 2001. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69:1593-98
40. McMillan DJ, Batzloff MR, Browning CL, et al. 2004. Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 22:2783-90
41. Tettelin H, Masignani V, Cieslewicz MJ, et al. 2002. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc. Natl. Acad. Sci. USA 99:12391-96
42. Ross BC, Czajkowski L, Hocking D, et al. 2001. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19:4135-42
43. Grandi G. 2003. Rational antibacterial vaccine design through genomic technologies. Int. J. Parasitol. 33:615-20
44. Tettelin H, Nelson KE, Paulsen IT, et al. 2001. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 293:498-506
45. Griffen AL, Becker MR, Lyons SR, et al. 1998. Prevalence of Porphyromonas gingivalis and periodontal health status. J. Clin. Microbiol. 36:3239-42
46. Stephens RS, ed. 1999. Chlamydia: Intracellular Biology, Pathogenesis and Immunity. Washington, DC: Am. Soc. Microbiol.
47. Montigiani S, Falugi F, Scarselli M, et al. 2002. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. 70:368-79
48. Etz H, Minh DB, Henics T, et al. 2002. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 99: 6573-78
49. Marra MA, Jones SJ, Astell CR, et al. 2003. The genome sequence of the SARS-associated coronavirus. Science 300:1399-1404
50. Rota PA, Oberste MS, Monroe SS, et al. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1393-99
51. Bukreyev A, Lamirande EW, Buchholz UJ, et al. 2004. Mucosal immunization of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363:2122-27
52. Yang Z-Y, Kong WP, Huang Y, et al. 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428:561-64
53. Sherman DR, Gwinn KM, Hickey MJ, et al. 2004. Mycobacterium tuberculosis H37Rv: Delta RD1 is more virulent than M. bovis bacilli Calmette-Guerin in long-term murine infection. J. Infect. Dis. 190:123-26
54. Groot AS, Rappuoli R. 2004. Genome-derived vaccines. Expert Rev. Vaccines 3: 59-76
55. + T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur. J. Immunol. 31:3816-24
56. Baraldo K, Mori E, Bartoloni A, et al. 2004. N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccine. Infect. Immun. 72:4884-87
57. Grifantini R, Finco O, Bartoloni E, et al. 1998. Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Eur. J. Immunol. 28:1225-32
58. Mateo L, Gardner J, Chen O, et al. 1999. An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J. Immunol. 163:4058-63
59. Ghosh MK, Li CI, Fayolle C, et al. 2002. Induction of HLA-A2-restricted CTL responses by a tubular structure carrying human melanoma epitopes. Vaccine 20:2463-73
60. Traggiai E, Becker S, Subbarao K, et al. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871-75
61. Garcia-Suarez Mdel M, Cima-Cabal MD, Florez N, et al. 2004. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect. Immun. 72:4534-40